Loading organizations...
§ Private Profile · Coppell, TX, USA
ZS Pharma is a technology company.
ZS Pharma was a biopharmaceutical company developing novel treatments for serious conditions, principally hyperkalemia. It leveraged proprietary ion-trap technology to create non-absorbed drugs, specifically managing dangerous potassium elevations. This innovative approach offered improved options where existing treatments fell short.
Founded in 2008 by Dr. Al Guillem and Dr. Jeff Keyser, ZS Pharma utilized prior experience from Adams Laboratories. Their core insight was to address critical unmet needs by challenging therapeutic norms, developing innovative, non-systemically absorbed compounds for patient benefit.
ZS Pharma's products targeted patients with hyperkalemia, a significant risk for those with kidney disease or heart failure. The company's vision centered on advancing highly specific, effective therapeutic solutions via targeted drug delivery. This commitment aimed to provide safer, impactful interventions for populations with limited treatment alternatives.
ZS Pharma has raised $147.0M across 3 funding rounds.
ZS Pharma has raised $147.0M in total across 3 funding rounds.
ZS (formerly ZS Associates) is a global management consulting and technology firm specializing in analytics, AI-driven platforms, and solutions for life sciences, pharmaceuticals, biotech, and other industries like financial services and high-tech. Founded with a focus on sales force optimization, it now partners with top pharmaceutical companies (serving 48 of the top 50) and medtech firms (21 of the top 25) to solve complex challenges in R&D, commercial operations, and patient outcomes using tools like the ZAIDYN® cloud platform and Max.AI for autonomous agents[1][3][4]. These solutions streamline sales performance (boosting client sales by 15-30%), accelerate drug development, and enable data-driven decisions, with over 100,000 pharma reps and 10,000+ users relying on its technology[1].
ZS was founded in 1983 in Evanston, Illinois, by Prabhakant Sinha and Andris Zoltners, two professors who pioneered sales force sizing and territory alignment models for pharmaceuticals[3][5]. Starting with just a handful of projects, by 1986 the firm had assisted eight of the ten largest pharma companies across the US, Canada, and Europe, growing to 25 members while handling 100+ projects in a dozen countries[5]. Key early traction came from reorganizing massive sales teams, developing incentive compensation designs, and evolving into analytics and software in the 1990s—earning the 2004 INFORMS Marketing Science Practice Prize for their territory alignment system[5]. Today, with 12,000+ employees across 35+ offices, ZS has expanded from pharma roots to a full-spectrum consulting powerhouse[3].
ZS stands out through its blend of deep industry science, advanced analytics, and practical tech implementation. Key strengths include:
ZS rides the convergence of AI, data analytics, and digital transformation in life sciences, where rising R&D costs and elusive commercial success demand simulation-first trials and patient-centric ecosystems[1][2]. Timing is ideal amid AI adoption surges in pharma (as seen in Brazil, India, China trends) and biosimilar growth shaped by HCP attitudes, positioning ZS to influence faster drug development and equitable healthcare[6]. Market forces like cloud-native platforms and in silico methods favor its tools, enabling biopharma like Theratechnologies and Boehringer Ingelheim to enhance field forces and customer experiences[4]. By partnering with industry leaders and embedding health equity, ZS shapes a connected healthcare ecosystem, amplifying innovation beyond consulting[3].
ZS is poised to lead AI-driven R&D revolutions, expanding Max.AI and ZS Discovery amid demands for cost-effective therapeutics and simulation-based trials. Trends like global AI uptake in pharma, biosimilar expansion, and digital operating models will propel growth, potentially deepening influence in emerging biopharma and beyond-life-sciences sectors. As it evolves from sales optimization pioneer to full tech ecosystem enabler, ZS will continue transforming challenges into patient-impacting results, solidifying its role at the intersection of science, data, and business.
ZS Pharma has raised $147.0M across 3 funding rounds. Most recently, it raised $55.0M Series D in March 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2014 | $55M Series D | Novo Holdings | Rivervest, 3X5 Special Opportunity Fund, Adage Capital Management, Alta Partners, Devon Park Bioventures, RA Capital Management, RiverVest Venture Partners, Salem Partners, Sofinnova Investments | Announced |
| Oct 28, 2012 | $46M Venture Round | Robert Alexander | 3X5 Special Opportunity Fund, Devon Park Bioventures, John Mckearn, Salem Partners | Announced |
| Oct 1, 2012 | $46M Series C | Alta Partners | Rivervest, 3X5 Special Opportunity Fund, Devon Park Bioventures, RiverVest Venture Partners, Salem Partners | Announced |
ZS Pharma has raised $147.0M in total across 3 funding rounds.
ZS Pharma's investors include Novo Holdings, RiverVest, 3x5 Special Opportunity Fund, Adage Capital Management, Alta Partners, Devon Park Bioventures, RA Capital Management, RiverVest Venture Partners, Salem Partners, Sofinnova Ventures, Robert Alexander, John McKearn.